The Therapeutic Goods Administration (TGA) Approved PEMAZYRE (Pemigatinib)
Summary: Australia has authorised the use of a new targeted therapy for the treatment of cholangiocarcinoma, a rare bile duct cancer. The…
Summary: Australia has authorised the use of a new targeted therapy for the treatment of cholangiocarcinoma, a rare bile duct cancer. The…
Synopsis : This marks the second indication for Pemazyre, which received accelerated FDA approval in 2020 for adults with previously treated, unresectable…